Survival and recurrence free benefits with different lymphadenectomy for resectable gastric cancer: A meta-analysis

Journal of Surgical Oncology

Volumn 107, Issue 8, 2013, Pages 807-814

  Jiang, Lei ^a   Yang, Ke Hu ^a   Guan, Quan Lin ^a   Zhao, Peng ^a   Chen, Yan ^a   Tian, Jin Hui ^a  

^a LANZHOU UNIVERSITY   (China)

Author keywords

D1 lymphadenectomy; D3 iymphadenectomy; gastric cancer; meta analysis, D2 lymphadenectomy

Indexed keywords

ARTICLE; CANCER SURGERY; CANCER SURVIVAL; CONFIDENCE INTERVAL; DATA EXTRACTION; DISEASE FREE SURVIVAL; HAZARD RATIO; HUMAN; LYMPH NODE DISSECTION; META ANALYSIS; OVERALL SURVIVAL; PANCREAS RESECTION; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; SPLENECTOMY; STOMACH CANCER; SURGICAL RISK;

ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; GASTRECTOMY; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATECTOMY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SPLENECTOMY; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84878278624     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23325     Document Type: Article

References (72)

1. Yamamoto S: Stomach cancer incidence in the world. Jpn J Clin Oncol 2001;31:471.
2. Crew KD, Neugut AI: Epidemiology of gastric cancer. World Gastroenterol 2006;12:354-362. (Pubitemid 43329250)
3. Yao JC, Mansfield PF, Pisters PW, et al.: Combined-modality therapy for gastric cancer. Semin Surg Oncol 2003;21:223-227. (Pubitemid 37521719)
4. de Bree E, Charalampakis V, Melissas J, et al.: The extent of lymph node dissection for gastric cancer: A critical appraisal. Surg Oncol 2010;102:552-562.
5. Biffi R, Botteri E, Cenciarelli S, et al.: Impact on survival of the number of lymph nodes removed in patients with node-negative gastric cancer submitted to extended lymph node dissection. Eur J Surg Oncol 2011;37:305-311.
6. Ohgaki M, Toshio T, Akeo H, et al.: Effect of extensive lymph node dissection on the survival of early gastric cancer. Hepatogastroenterology 1999;46:2096-2099. (Pubitemid 29366405)
7. Reis E, Kama NA, Doganay M, et al.: Long-term survival is improved by an extended lymph node dissection in potentially curable gastric cancer. Hepatogastroenterology 2002;49:1167-1171. (Pubitemid 34809813)
8. Cady B: Lymph node, metastases. Indicators, but not governors of survival. Arch Surg 1984;119:1067-1072. (Pubitemid 14037331)
9. Park SS, Park JM, Kim JH, et al.: Prognostic factors for patients with node-negative gastric cancer: Can extended lymph node dissection have a survival benefit? J Surg Oncol 2006;94:16-20.
10. Kajitani T: The general rules for the gastric cancer study in surgery and pathology. Part I. Clinical classification. Jpn J Surg 1981;11:127-139. (Pubitemid 11080134)
11. Tamura S, Takeno A, Miki H: Lymph node dissection in curative gastrectomy for advanced gastric cancer. Int J Surg Oncol 2011;2011:748745.
12. Hartgrink HH, van de Velde CJ, Putter H, et al.: Extended lymph node dissection for gastric cancer: Who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol 2004;22:2069-2077. (Pubitemid 41095139)
13. Cuschieri A, Weeden S, Fielding J, et al.: Patient survival after D1 and D2 resections for gastric cancer: Long-term results of the MRC randomized surgical trial Surgical Co-operative Group. Br J Cancer 1999;79:1522-1530. (Pubitemid 29116815)
14. Lustosa SA, Saconato H, Atallah AN, et al.: Impact of extended lymphadenectomy on morbidity, mortality, recurrence and 5- year survival after gastrectomy for cancer. Meta-analysis of randomized clinical trials. Acta Cir Bras 2008;23:520-530.
15. Yang SH, Zhang YC, Yang KH, et al.: An evidence-based medicine review of lymphadenectomy extent for gastric cancer. Am J Surg 2009;197:246-251.
16. Wu CW, Hsiung CA, Lo SS, et al.: Nodal dissection for patients with gastric cancer: A randomised controlled trial. Lancet Oncol 2006;7:309-315.
17. Songun I, Putter H, Kranenbarg EM, et al.: Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010;11:439-449.
18. Baba M, Hokita S, Natsugoe S, et al.: Paraaortic lymphadenectomy in patients with advanced carcinoma of the upper-third of the stomach. Hepatogastroenterology 2000;47:893-896. (Pubitemid 30417319)
19. Isozaki H, Okajima K, Fujii K, et al.: Effectiveness of paraaortic lymph node dissection for advanced gastric cancer. Hepatogastroenterology 1999;46:549-554. (Pubitemid 29154815)
20. Maeta M, Yamashiro H, Saito H, et al.: A prospective pilot study of extended (D3) and superextended para-aortic lymphadenectomy (D4) in patients with T3 or T4 gastric cancer managed by total gastrectomy. Surgery 1999;125:325-331. (Pubitemid 29168820)
21. Yonemura Y, Segawa M, Matsumoto H, et al.: Surgical results of performing R4 gastrectomy for gastric cancer located in the upper third of the stomach. Surg Today 1994;24:488-493. (Pubitemid 24235299)
22. Sasako M, Sano T, Yamamoto S, et al.: D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 2008;359:453-462.
23. Chen XZ, Hu JK, Zhou ZG, et al.: Meta-analysis of effectiveness and safety of D2 plus para-aortic lymphadenectomy for resectable gastric cancer. J Am Coll Surg 2010;210:100-105.
24. Wang XF, Sun YH, Liang DJ, et al.: Clinical values of extended lymph node dissection for gastric cancer: A meta-analysis for D1 versus D2 gastrectomy. Zhonghua Wei Chang Wai Ke Za Zhi 2007;10:425-430.
25. Memon MA, Subramanya MS, Khan S, et al.: Meta-analysis of D1 versus D2 gastrectomy for gastric adenocarcinoma. Ann Surg 2011;253:900-911.
26. Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration; 2011. Available from www. cochrane-handbook.org
27. Parmar MK, Torri V, Stewart L: Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998;17:2815-2834. (Pubitemid 28562978)
28. Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-1558. (Pubitemid 34746062)
29. Higgins JP, Thompson SG, Deeks JJ, et al.: Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560. (Pubitemid 37088507)
30. Bonenkamp JJ, Songun I, Hermans J, et al.: Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 1995;345:745-748.
31. Bonenkamp JJ, Hermans J, Sasako M, et al.: Extended lymphnode dissection for gastric cancer. N Engl J Med 1999;340:908-914. (Pubitemid 29141051)
32. Cuschieri A, Fayers P, Fielding J, et al.: Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: Preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet 1996;347:995-999. (Pubitemid 26112171)
33. Wu CW, Hsiung CA, Lo SS, et al.: Randomized clinical trial of morbidity after D1 and D3 surgery for gastric cancer. Br J Surg 2004;91:283-287. (Pubitemid 38375766)
34. Degiuli M, Sasako M, Calgaro M, et al.: Morbidity and mortality after D1 and D2 gastrectomy for cancer: Interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomised surgical trial. Eur J Surg Oncol 2004;30:303-308. (Pubitemid 38425649)
35. Sano T, Sasako M, Yamamoto S, et al.: Gastric cancer surgery: Morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy-Japan Clinical Oncology Group study 9501. J Clin Oncol 2004;22:2767-2773. (Pubitemid 41079893)
36. Yoshikawa T, Sasako M, Sano T, et al.: Stage migration caused by D2 dissection with para-aortic lymphadenectomy for gastric cancer from the results of a prospective randomized controlled trial. Br J Surg 2006;93:1526-1529. (Pubitemid 44893655)
37. Yonemura Y, Wu CC, Fukushima N, et al.: Operative morbidity and mortality after D2 and D4 extended dissection for advanced gastric cancer: A prospective randomized trial conducted by Asian surgeons. Hepatogastroenterology 2006;53: 389-394. (Pubitemid 43954414)
38. Robertson CS, Chung SC, Woods SD, et al.: A prospective randomized trial comparing R1 subtotal gastrectomy with R3 total gastrectomy for antral cancer. Ann Surg 1994;220:176-182. (Pubitemid 24309416)
39. Degiuli M, Sasako M, Ponti A: Morbidity and mortality in the Italian Gastric Cancer Study Group randomized clinical trial of D1 versus D2 resection for gastric cancer. Br J Surg 2010;97:643-649.
40. Dent DM, Madden MV, Price SK: Randomized comparison of R1 and R2 gastrectomy for gastric carcinoma. Br J Surg 1988; 75:110-112. (Pubitemid 18078521)
41. Bonenkamp JJ, van de Velde CJ, Sasako M, et al.: R2 compared with R1 resection for gastric cancer: Morbidity and mortality in a prospective, randomised trial. Eur J Surg 1992;158:413-418.
42. Bunt AM, Hermans J, Smit VT, et al.: Surgical/pathologic-stage migration confounds comparisons of gastric cancer survival rates between Japan and Western countries. J Clin Oncol 1995;13:19-25.
43. Kulig J, Popiela T, Kolodziejczyk P, et al.: Standard D2 versus extended D2 (D2+) lymphadenectomy for gastric cancer: An interim safety analysis of a multicenter, randomized, clinical trial. Am J Surg 2007;193:10-15. (Pubitemid 44937167)
44. Yonemura Y, Wu CC, Fukushima N, et al.: Randomized clinical trial of D2 and extended paraaortic lymphadenectomy in patients with gastric cancer. Int J Clin Oncol 2008;13:132-137. (Pubitemid 351668170)
45. Jing BJ, Gao YF, Sun RX, et al.: Clinical study on the dissection of lmyph nodes around abdominal aortic artery in advanced gastric cancer. Chin J Gener Surg 2000;9:292-295.
46. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 2nd English edition. Gastric Cancer 1998; 1:10-24.
47. Danielson H, Kokkola A, Kiviluoto T, et al.: Clinical outcome after D1 vs. D 2-3 gastrectomy for treatment of gastric cancer. Scand J Surg 2007;96:35-40. (Pubitemid 46493762)
48. Ramacciato G, Aurello P, D'Angelo F, et al.: Does extended lymphadenectomy influence prognosis of gastric carcinoma after curative resection? Hepatogastroenterology 2000;47:1470-1474.
49. Seevaratnam R, Bocicariu A, Cardoso R, et al.: A meta-analysis of D1 versus D2 lymph node dissection. Gastric Cancer 2011;15:S60-69.
50. Tokunaga M, Ohyama S, Hiki N, et al.: Can superextended lymph node dissection be justified for gastric cancer with pathologically positive para-aortic lymph nodes? Ann Surg Oncol 2010;17:2031-2036.
51. Degiuli M, Sasako M, Ponti A, et al.: Survival results of a multicentre phase II study to evaluate D2 gastrectomy for gastric cancer. Br J Cancer 2004;90:1727-1732. (Pubitemid 38725642)
52. Degiuli M, Sasako M, Ponti A, et al.: Morbidity and mortality after D2 gastrectomy for gastric cancer: Results of the Italian Gastric Cancer Study Group prospective multicenter surgical study. J Clin Oncol 1998;16:1490-1493. (Pubitemid 28175770)
53. Viudez-Berral A, Miranda-Murua C, Arias-de-la-Vega F, et al.: Current management of gastric cancer. Rev Esp Enferm Dig 2012;104:134-141.
54. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 ver 3. Gastric Cancer 2011;14:113-123.
55. Japanese Gastric Cancer Association. Japanese Research Society for gastric cancer Japanese classification of gastric cancer. First English Edition. Tokyo: Kancehara & Co., Ltd; 1995.
56. Biffi R, Chiappa A, Luca F, et al.: Extended lymph node dissection without routine spleno-pancreatectomy for treatment of gastric cancer: Low morbidity and mortality rates in a single center series of 250 patients. J Surg Oncol 2006;93:394-400.
57. Krijnen P, den Dulk M, Meershoek-Klein Kranenbarg E, et al.: Improved survival after resectable non-cardia gastric cancer in The Netherlands: The importance of surgical training and quality control. Eur J Surg Oncol 2009;35:715-720.
58. Dimick JB, Birkmeyer JD, Upchurch GR, Jr.: Measuring surgical quality: What's the role of provider volume? World J Surg 2005;29:1217-1221. (Pubitemid 41625962)
59. Finlayson SR: The volume-outcome debate revisited. Am Surg 2006;72:1038-1042; discussion 1061-1039, 1133-1048. (Pubitemid 351837928)
60. Gruen RL, Pitt V, Green S, et al.: The effect of provider case volume on cancer mortality: Systematic review and meta-analysis. CA Cancer J Clin 2009;59:192-211.
61. Thompson AM, Rapson T, Gilbert FJ, et al.: Hospital volume does not influence long-term survival of patients undergoing surgery for oesophageal or gastric cancer. Br J Surg 2007; 94:578-584. (Pubitemid 46732241)
62. Damhuis RA, Meurs CJ, Dijkhuis CM, et al.: Hospital volume and post-operative mortality after resection for gastric cancer. Eur J Surg Oncol 2002;28:401-405.
63. Dikken JL, Dassen AE, Lemmens VE, et al.: Effect of hospital volume on postoperative mortality and survival after oesophageal and gastric cancer surgery in the Netherlands between 1989 and 2009. Eur J Cancer 2012;48:1004-1013.
64. Bunt AM, Hermans J, Boon MC, et al.: Evaluation of the extent of lymphadenectomy in a randomized trial of Western- versus Japanese-type surgery in gastric cancer. J Clin Oncol 1994; 12:417-422. (Pubitemid 24056418)
65. Wu CW, Hsieh MC, Lo SS, et al.: Results of curative gastrectomy for carcinoma of the distal third of the stomach. J Am Coll Surg 1996;183:201-207.
66. Lee JH, Ryu KW, Park SR, et al.: Learning curve for total gastrectomy with D2 lymph node dissection: Cumulative sum analysis for qualified surgery. Ann Surg Oncol 2006;13:1175-1181. (Pubitemid 44440418)
67. Dikken JL, van Sandick JW, Maurits Swellengrebel HA, et al.: Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS). BMC Cancer 2011;11:329.
68. Cunningham D, Allum WH, Stenning SP, et al.: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-120.
69. Sakuramoto S, Sasako M, Yamaguchi T, et al.: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810-1820. (Pubitemid 350044801)
70. Bang YJ, Kim YW, Yang HK, et al.: Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): A phase 3 open-label, randomised controlled trial. Lancet 2012;379:315-321.
71. Paoletti X, Oba K, Burzykowski T, et al.: Benefit of adjuvant chemotherapy for resectable gastric cancer: A meta-analysis. JAMA 2010;303:1729-1737.
72. Bang YJ, Van Cutsem E, Feyereislova A, et al.: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastrooesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-697.